Skip to main content
SpringerLink
Log in

Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma

  • Phase II Clinical Trials
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Comis RL: DTIC in malignant melanoma: A perspective. Cancer Treat Rep 60:165–176, 1976

    Google Scholar 

  2. Carbone PP, Costello W: Eastern Cooperative Oncolgy Group studies with DTIC (NSC-45388). Cancer Treat Rep 60:193–198, 1976

    Google Scholar 

  3. Ahmann DL: Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep 60:747–751, 1976

    Google Scholar 

  4. Luce JK: Chemotherapy of malignant melanoma. Cancer 30:1604–1615, 1972

    Google Scholar 

  5. Carter SK, Friedman MA: 5(3,3 Dimethyl-1-triazeno)-immidazole-4-carboxamide (DTIC, DIC, NSC-45388) — a new antitumor agent with activity against malignant melanoma. Eur J Cancer 8:85–92, 1972

    Google Scholar 

  6. Benjamin RS: Chemotherapy of malignant melanoma. World J Surg 3:321–328, 1979

    Google Scholar 

  7. Comis RL, Carter SK: Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev 1:285–304, 1974

    Google Scholar 

  8. Costanza ME, Nathanson L, Schoenfeld D, Wolter J, Colsky J, Regelson W, Cunningham T, Sedransk N: Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 40:1010–1015, 1977

    Google Scholar 

  9. Von Hoff DD, Amato DA, Kaufman JH, Falkson G, Cunningham TJ:, Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma. Am J Clin Oncol (CCT) 7:135–139, 1984

    Google Scholar 

  10. Livingston RB, Carter SK: Single agents in cancer chemotherapy. Plenum Press, New York, 1970

    Google Scholar 

  11. Csányi E, Halàsz M: Cross-resistance studies on 1,6-dibromo-dideoxy-D-mannitol (DBM)-resistant Yoshida S.C. sarcoma. Brit J Cancer 21:353–357, 1967

    Google Scholar 

  12. Mischler NE, Earhart RH, Carr B, Tormey DC: Dibromodulcitol. Cancer Treat Rev 8:191–204, 1979

    Google Scholar 

  13. Belej MA, Troetel WM, Weiss AJ, Stambaugh JE, Manthei RW: The absorption and metabolism of dibromodulcitol in patients with advanced cancer. Clin Pharmacol Ther 13:563–572, 1972

    Google Scholar 

  14. Andrews NC, Weiss AJ, Ansfield FJ, Rochlin DB, Mason JH: Phase I study of dibromodulcitol (NSC-104800). Cancer Chemother Rep 55:61–65, 1971

    Google Scholar 

  15. Andrews NC, Wiess AJ, Wilson W, Nealon T: Phase II study of dibromodulcitol (NCS-104800), Cancer Chemother Rep 58:653–660, 1974

    Google Scholar 

  16. Phillips RW, Brook J: Clinical experiences with dibromodulcitol (NCS-104800) in solid tumors. Cancer Chemother Rep 55:567–573, 1971

    Google Scholar 

  17. Bellet RE, Catalano RB, Mastrangelo MJ, Berd D: Positive phase II trial of dibromodulcitol in patients with metastatic melanoma refractory to DTIC and a nitrosourea. Cancer Treat Rep 62:2095–2099, 1978

    Google Scholar 

  18. Medina W, Kirkwood JM: Phase II trial of mitolactol in patients with metastatic melanoma. Cancer Treat Rep 66:195–196, 1982

    Google Scholar 

  19. Maiden LT, Coates AS, Milton GW, McCarthy WH, Levi JA, Woods RL, Byrne MJ, Reynolds PM, Fox RM, Hedley DW, Raghavan D, Tattersall MHN: Mitolactol chemotherapy for malignant melanoma: a phase II study. Cancer Treat Rep 68:1045–1046, 1984

    Google Scholar 

  20. Zelen M: The randomization and stratification of patients to clinical trials. J Chron Dis 27:365–375, 1974

    Google Scholar 

  21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (CCT) 5:649–655, 1982

    Google Scholar 

  22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute and Harvard School of Public Health, (CA 23318), Boston, MA

    David A. Amato & Arlene Ash

  2. University of Rochester Cancer Center, (CA 11083), Rochester, NY

    Howard Bruckner & Edwin D. Savlov

  3. Cancer Center, Hospital of the University of Pennsylvania, (CA 15488), Philadelphia, PA

    DuPont Guerry IV

  4. University of Pretoria, (CA 21692), Pretoria, South Africa

    Geoffrey Falkson

  5. University of Wisconsin Clinical Cancer Center, (CA 21076), Madison, WI

    Ernest C. Borden

  6. Fox Chase Cancer Center, (CA 18281), Philadelphia, PA

    Richard H. Creech

  7. Albany Medical College, (CA 06594), Albany, NY, USA

    Thomas J. Cunningham

Authors
  1. David A. Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard Bruckner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. DuPont Guerry IV
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arlene Ash
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Geoffrey Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ernest C. Borden
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Richard H. Creech
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Edwin D. Savlov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Thomas J. Cunningham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amato, D.A., Bruckner, H., Guerry, D. et al. Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. Invest New Drugs 5, 293–297 (1987). https://doi.org/10.1007/BF00175301

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00175301

Key words

Search

Navigation